Additionally, as has been shown previously with RV79, they found that MYXV could inhibit systemic in vivo engraftment of human MM cells into immunodeficient mice, by effectively purging primary CD138+ MM cells contaminating patient hematopoietic products78. This evidence concerns the gene SDC1 and Miyoshi myopathy.